Quest Raises Guidance Straight Into a $120 Million PAMA Hole
A 10% growth quarter, a stock at highs, and a Medicare rate cut that just got bigger — with the data behind it now under open attack.
DGX · Earnings Call · 2026-10-22
Quest Diagnostics did almost everything a shareholder could ask for in the third quarter. Revenue rose 10% to $3.1 billion, adjusted EPS jumped 15.4% to $3.00, and management raised full-year guidance to $12.065–$12.105 billion in revenue and $11.25–$11.35 in adjusted EPS. Total volume, measured in requisitions, climbed 14.5%; strip out the Corewell and Fresenius relationships and volume growth was still 5%, with revenue per requisition up 1.7% excluding that mix. Adjusted operating margin expanded 40 basis points to 16.7%, and cash from operations ran $1.49 billion year to date. The last filed quarter showed total revenue of $3.0 billion, up 10% year over year and extending a 17-year climb of roughly 60%.
The engine management wants you to see
The growth story has a new front door: the Apple Health app. iPhone and iPad users will be able to purchase, schedule, and receive results for more than 50 biomarkers — ApoB, Lp(a), and a biometrics overlay at Quest's 2,000 patient service centers — directly inside Apple's health ecosystem. Jim Davis put a price on it: “It is $119 rack, the types of biomarkers.” — Jim Davis, Chairman, Chief Executive Officer, and President · 2026-10-22 The strategic point is not the $119. It is that Sam Samad described the channel as margin-accretive because there are “no denials, no patient concessions” — Sam Samad, Chief Financial Officer · 2026-10-22 — cash pay, dense requisitions that can run ten tests apiece. That is the cleanest revenue in diagnostics, and it is why the consumer health channel is expected to grow north of 30% this year. The Fresenius relationship has opened a second adjacency: a dedicated sales force calling on nephrologists for early-stage kidney disease testing, a physician call point Quest previously did not own.The hole got bigger, and the data is now the argument
Then there is PAMA, and this is where the quarter's tone shifts. CMS has proposed 2027 rate cuts that management sizes at roughly $120 million, or about 1% of total company revenue, with a cumulative impact below 1.3% of revenue across 2027–2029. That is a bigger number than the one Quest carried into the year. Last October, Sam Samad framed it plainly: “it's a $100 million impact next year if PAMA does come back.” — Sam Samad, Chief Financial Officer · 2025-10-21 The offset language has not changed — “We intend to offset a portion of it.” — Sam Samad, Chief Financial Officer · 2026-10-22 — but the denominator moved, and analysts noticed. Luke Sergott of Barclays pressed Davis on why the estimate sharpened from $100 million to $120 million-plus after the data came out; Davis's answer was that 775 of roughly 1,550 codes face the maximum 15% cut, worse than anyone expected. What is genuinely new is the attack on the data itself. CMS released segment-level detail showing that independent labs accounted for 76.5% of reported volume, while hospital outreach was under 10%. Davis did not hide his contempt for the data collection process:That argument is the entire lobbying case for the RESULTS Act, which now has more than 135 co-sponsors and is waiting on a CBO score expected in mid-to-late November. Management wants the legislation attached to a year-end package. The budgeting process is where the offset will be decided, and Sam Samad was explicit that the street should not model the full hit. But he would not quantify the offset either, which leaves the market with a $120 million gross number and a promise.On the new, what they released yesterday is that the independents represented 76.5% of the volume reported. Again, it is way overestimating the share that independent labs have.
What Quest stopped saying
The quiet tell is in the company's own keyword history. Last quarter, Bad debt was the single highest-ranked theme on Quest's call — analysts were pressing on hospital client-bill exposure after a hospital preannouncement. This quarter it is gone, replaced by Patient price concessions and a DSO question. The answer was the same as last time: “we are not seeing any meaningful change in terms of bad debt.” — Sam Samad, Chief Financial Officer · 2026-07-23 DSO is up about three days, attributed to client-bill mix and fewer banking days. The balance sheet shows the strain more objectively: receivables at 54.7% of revenue, up 3.4 points year over year. The other thing that dropped into the call almost in passing is a cybersecurity 8-K. Sam Samad confirmed unauthorized access to a test-ordering system used by clients without an EMR, then shut it down: “The investigation is in its early stages. We are not in a position right now to provide any more information” — Sam Samad, Chief Financial Officer · 2026-10-22. It did not materially disrupt operations, per the filing, but it is the kind of disclosure that tends to get louder before it gets quieter. Meanwhile the ACA overhang has quietly shrunk. Exchange-related requisition volume fell 11%, but tests per requisition rose 8%, netting to roughly a 10 basis point revenue loss — higher-acuity patients staying in the pool. That is a better outcome than the ACA market scare that dominated healthcare calls earlier in the year, and it is why the exchange issue barely surfaced in Q&A.The tape is betting on Congress
Here is the contrast that matters. Quest stock is up 21% over the last 90 days, closing within 3% of its high, even though CMS's preliminary cut disclosure knocked the shares down 5.1% on September 22. The market has decided the PAMA hit is either deferrable or offsettable. At 14.4 times operating income, with $300 million of stock retired in the quarter and net debt of about $5.0 billion, there is not a lot of room for a negative surprise on the offset. Davis's closing argument on the cost side is the one to remember:He is right that the Invigorate program has been offsetting $120 million of annual wage pressure for years, and that volume leverage in a high-fixed-cost lab is real. But 2027 also laps the Corewell and Fresenius revenue contribution, which added roughly 3% to growth this year and will not repeat. The PAMA impact, the lapping, and a full multiple are all arriving in the same January guidance call. The quarter was good. The story is now legislative, and the stock is already voting yes.Is 100% of that going to drop to the bottom line? Absolutely not. ... The best way to offset this is to grow our way out of it.